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1128 The Journal of Thoracic and CardObjective: We propose that the fetal heart is highly resilient to hypoxic stress. Our
objective was to elucidate the human fetal gene expression profile in response to
simulated ischemia and reperfusion to identify molecular targets that account for the
innate cardioprotection exhibited by the fetal phenotype.
Methods: Primary cultures of human fetal cardiac myocytes (gestational age, 15-20
weeks) were exposed to simulated ischemia and reperfusion in vitro by using a
simulated ischemic buffer under anoxic conditions. Total RNA from treated and
baseline cells were isolated, reverse transcribed, and labeled with Cy3 or Cy5 and
hybridized to a human cDNA microarray for expression analysis. This analysis
revealed a highly significant (false discovery rate, 3%) suppression of interleukin
6 transcript levels during the reperfusion phase confirmed by means of quantitative
polymerase chain reaction (0.25  0.11-fold). Interleukin 6 signaling during isch-
emia and reperfusion was assessed at the protein expression level by means of
Western measurements of interleukin 6 receptor, the signaling subunit of the
interleukin 6 receptor complex (gp130), and signal transducer of activated tran-
scription 3. Posttranslational changes in the protein kinase B signaling pathway
were determined on the basis of the phosphorylation status of protein kinase B,
mitogen-activated protein kinase, and glycogen synthase kinase 3. The effect of
suppression of a prohypertrophic kinase, integrin-linked kinase, with short-interfer-
ing RNA was determined in an ischemia and reperfusion–stressed neonatal rat
cardiac myocyte model. Endogenous secretion of interleukin 6 protein in culture
supernatants was measured by enzyme-linked immunosorbent assay.
Results: Human fetal cardiac myocytes exhibited a significantly lower rate of apoptosis
induction during ischemia and reperfusion and after exposure to staurosporine and
recombinant interleukin 6 compared with that observed in neonatal rat cardiac myocytes
(P  .05 for all comparisons, analysis of variance). Exposure to exogenously added
recombinant interleukin 6 increased the apoptotic rate in both rat and human fetal
cardiac myocytes (P  .05). Short-interfering RNA–mediated suppression of integrin-
linked kinase, a prohypertrophy upstream kinase regulating protein kinase B and
glycogen synthase kinase 3 phosphorylation, was cytoprotective against ischemia and
reperfusion–induced apoptosis in neonatal rat cardiac myocytes (P  .05).
Conclusions: Human fetal cardiac myocytes exhibit a uniquely adaptive transcrip-
tional response to ischemia and reperfusion that is associated with an apoptosis-
resistant phenotype. The stress-inducible fetal cardiac myocyte gene repertoire is a
useful platform for identification of targets relevant to the mitigation of cardiac
ischemic injury and highlights a novel avenue involving interleukin 6 modulation
for preventing the cardiac myocyte injury associated with ischemia and reperfusion.
T he idea that the immature heart has an inherently greater capacity to resiststress associated with hypoxia is supported by several investigations,1,2although contradictory interpretations have been made that appear to be
model dependent.3,4 There is no PubMed-precedented information, however, re-
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Dgarding potential developmental changes in cardiomyocyte
gene expression, which might reveal the molecular mecha-
nisms accounting for the enhanced stress resistance in the
immature human cardiac myocyte.
The idea that interleukin (IL) 6 pathway activation ad-
versely affects cardiac function is solidly supported by
clinical studies indicating that IL-6 and its specific receptor
(IL-6R) and the 130-kd glycoprotein signaling subunit of
the IL-6 receptor, gp130,5 are upregulated at the mRNA and
TABLE 1. Lists of differentially expressed genes during is
the text
Unigene cluster ID Alias
Group A Repression during ischemia (I) and re
Hs.74615 Platelet-derived growth factor recepto
Hs.433989 Decorin
Hs.179573 Collagen, type I, alpha 2
Hs.119129 Collagen, type IV, alpha 1
Hs.87409 Thrombospondin 1
Hs.458104 Mitogen-activated protein-kinase 1
Hs.274464 Diaphorase (NADH) (cytochrome b-5
Hs.93913 Interleukin 6
Hs.75636 Likely ortholog of mouse myosin light
Group B Repression during ischemia
Hs.344080 Chromosome 6 open reading frame 15
Hs.185973 Degenerative spermatocyte homolog,
Hs.348389 Sideroflexin 1
Hs.90998 Septin 6
Hs.194071 Hypothetical protein FLJ36812
Hs.168159 Bifunctional apoptosis regulator
Hs.246381 CD68 antigen
Hs.91299 Guanine nucleotide binding protein (G
Group C Activation during I/R
Hs.3094 KIAA0063
Hs.433205 Metallothionein 1E
Hs.457574 Hypothetical gene supported by AK02
Hs.8364 Pyruvate dehydrogenase kinase, isoe
Hs.405944 Immunoglobulin lambda locus
Hs.117848 Hemoglobin, epsilon 1
Hs.76847 Alpha glucosidase II alpha subunit
Hs.102950 Immunoglobulin lambda joining 3
Hs.194019 Attractin
Hs.82646 Hsp40
Hs.108972 Hypothetical protein LOC285705
Hs.154078 Lipopolysaccharide binding protein
Hs.372513 Glycophorin B
Group D Activation during I; repression during
Hs.227656 Polytropic retrovirus receptor
Hs.28805 Hypothetical protein LOC255512
Hs.85155 Early response factor-1 (ERF-1)
Unsupervised hierarchic clustering reveals 4 distinct expression strata, a
ischemia and 2 hours of reperfusion compared with control levels. The fa
available at http://genome-www5.stanford.edu/cgi-bin/source/sourceSearcprotein levels in the myocardium in patients with advanced
The Journal of Thoracicheart failure in comparison with a control group6 and by the
large increases in IL-6 plasma concentration that occur
during cardiopulmonary bypass.7 These studies, however,
do not differentiate between the inference that cardiac stress
engenders endogenous release of IL-6 as a protective re-
sponse and the diametrically opposed viewpoint that IL-6 is
per se causative of cardiac damage.
Cellular responses to IL-6 are elicited by binding of
soluble IL-6 cytokine to IL-6R. The signaling capacity
ia and reperfusion identified with SAM, as described in
Fold change
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sion (R)
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1.73 1.38
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1.47 0.97
1.27 1.22
1.33 0.84
1.15 0.76
1.15 0.63
wn in Figure 1. Fold changes are based on measurements at 4 hours of
column contains the Unigene cluster IDs, the annotations for which are
M, Significance Analysis for Microarray.chem
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Dment of 2 gp130 subunits to the activated, multisubunit
receptor complex. Activation of the IL-6 receptor-ligand
complex is dependent on the recruitment and dimeriza-
tion of gp130,8 which triggers activation of several col-
lateral signaling pathways, including the Janus kinase/
signal transducer and activator of transcription (JAK/
STAT), Ras/mitogen-activated protein kinase (MAPK),
and phosphatidylinositol 3– kinase (PI3-K)– dependent
pathway involving sequential phosphorylation of protein
kinase B (PKB/Akt) and glycogen synthase kinase 3
(GSK-3 ).9 Thus the IL-6 receptor complex consists of a
ligand-binding molecule (IL-6R) and a signaling sub-
unit, gp130, which provides a rapid membrane-to-
nucleus signaling system regulating inflammatory gene
expression.
We show here in expression-profiling experiments that
human fetal cardiac myocytes (HFCMs) exposed to simu-
lated ischemia with reperfusion (I/R) or without reperfusion
exhibit a uniquely adaptive transcriptional response. The
fetal response includes a limited number of functional clus-
ters dominated by predicted anti-inflammatory properties,
featuring repression of the IL-6 signaling evident at both the
mRNA and protein expression levels during reperfusion-
mediated stress. These data provide a plausible and thera-
peutically important explanation for the innately apoptosis-
resistant HFCM phenotype.
Methods
Cardiac Myocyte Cultures
Primary cultures of HFCMs were derived from structurally normal
hearts after elective pregnancy termination (gestational age, 15-20
weeks) under an institutional review board–approved protocol.
Primary cultures of cardiac myocytes were prepared from human
fetal ventricles and from 2- to 3-day neonatal rat cardiac myocytes
(NRCMs) by the following previously described protocol10 in
compliance with Institutional Animal Care Guidelines. Cardiomy-
ocytes were dissociated by means of repeated (3) enzymatic
digestion with 0.05% trypsin-collagenase solution (Life Technol-
ogies) at 37°C and the dissociated cells concentrated from the
supernatant by means of centrifugation (2600 rpm  7 minutes)
and plated at a density of 1  105 cells/cm2 on 35-mm culture
dishes with 2 mL of culture medium (Dulbeccco’s modified
Eagle’s medium with 10% fetal bovine serum). Preplating of
seeded cells onto 100-mm culture dishes to remove noncardiom-
yocytes yielded cultures containing approximately 80% -myosin
heavy chain–positive cardiac myocytes.
HFCMs and NRCMs were exposed to simulated I/R or isch-
emia without reperfusion in vitro for the indicated time intervals
by using ischemic buffer and anoxic conditions, as previously
described.11 To simulate ischemia, the cultures were washed twice
with phosphate-buffered saline and transferred to a pH 6.5 simu-
lated ischemia solution containing, in 100 mL of deionized water,
0.8 g of NaCl, 0.119 g of N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid, 0.164 g of 2-deoxyglucose, 0.89 mL of KCl,
0.472 mL of CaCl , 0.238 mL of MgCl , and 0.135 mL of2 2
DL-lactic acid saturated in 100% N2 for 1 hour, followed by
1130 The Journal of Thoracic and Cardiovascular Surgery ● Maaddition of 0.1 g of bovine serum albumin. Cultures were placed in
an airtight container at 37°C with 100% N2 inflow for periods
ranging from 2 to 24 hours and subsequently washed twice with
phosphate-buffered saline before harvesting. Cardiomyocyte cul-
tures were re-exposed to the control normoxic serum-free medium
to simulate reperfusion. Control cardiomyocyte cultures were
maintained under normoxic conditions at 37°C until analysis. Thus
ischemia is simulated by a combination of acidic pH, interference
with glucose metabolism, and anoxia, and reperfusion is simulated
by means of re-exposure to normoxia, which has been shown to
provoke extensive apoptosis in similar models12 and is herein
referred to as simulated I/R.
Microarray Gene Expression Analysis
RNA isolation, fluorescence labeling of cDNA, hybridization to
spotted arrays containing 15,264 sequence-verified cDNA clones,
and quantitative fluorescence scanning of gene expression inten-
sity were performed at the University of Toronto Health Network
Microarray Centre (www.microarray.ca), as previously reported
by us13 and others (for a list of publications, see http://www.
microarrays.ca/about/pub.html). Significance of changes in se-
quential gene expression in HFCMs exposed to I/R (at control, 4
hours of ischemia, and 4 hours of ischemia plus 4 hours of
reperfusion) were determined by means of repeated permutation of
MIAME-compliant (www.mged.org) data with Significance Anal-
ysis for Microarray.14 Results from the Significance Analysis for
Microarray analysis were visualized as hierarchic clusters in Gene
Traffic (www.iobion.com), and significant genes were classified by
their differential response to ischemia, reperfusion, or both. The
results shown in Table 1 and Figure 1 are based on 2 biologic and
2 technical (array) replicates at each indicated time point, with a
false discovery rate indicative of the statistical risk of incorrect
identification of differentially expressed genes set to less than
3%.15
Validation With Quantitative Polymerase Chain
Reaction
Independent confirmation of changes in IL-6 transcription levels
was performed by using real-time quantitative polymerase chain
reaction (qPCR), as previously described by us.13 Primers were
constructed against the 3= ends of IL-6, and amplicon abundance
was determined in real time with SYBR Green Dye (Applied
Biosystems) fluorescence measurement during the logarithmic
phase and normalized to that of a control gene, cyclophilin.
Western Blot Analysis
Fetal cardiomyocyte extracts containing 20 g of protein were sub-
jected to sodium dodecylsulfate–polyacrylamide gel electrophoresis
with 10% polyacrylamide gel and transferred onto Immobilon-P
transfer membranes (Millipore). Analysis was performed with poly-
clonal PKB antibody (Transduction Laboratories), polyclonal serine
437 catalytically active, phosphorylation-specific PKB antibody (Cell
Signaling Technology), polyclonal integrin-linked kinase (ILK) anti-
body (Upstate Biotechnology), and anti-IL-6 receptor (IL-6R) and
anti-gp130 antibodies (Santa Cruz Biotech). Monoclonal antibodies
used for the determination of total and phosphorylated GSK-3
protein levels were from Biosource; total and phosphorylated (Py705)
STAT-3, (Thr202/Tyr204) MAPK42/44, and stress-activated protein
y 2005
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Dkinase (SAPK-Thr183/Pyr185) monoclonal antibodies were from
Figure 1. Heat map with hierarchic clustering of genes showing
coherent expression patterns during ischemia (Isch) and reper-
fusion (R). Columns represent each of 2 different biologic repli-
cates, each performed with 2 (dye-swapped) array replicates at
each of the indicated time points. Red color indicates higher
expression, and green color indicates lower expression. Gene-
wise clustering reveals 4 temporally distinct expression strata: A,
repression during ischemia and reperfusion; B, repression during
ischemia; C, activation during ischemia, reperfusion, or both; and
D, activation during ischemia and repression during reperfusion.
The far right column contains the Unigene cluster ID, the anno-
tation for which is available at http://genome-www5.stanford.
edu/cgi-bin/source/sourceSearch. Genes with significantly differ-
ent expression values from control are indicated in Table 1.Cell Signaling.
The Journal of ThoracicIL-6 Measurements
IL-6 concentrations in the culture supernatants were determined by
using an enzyme-linked immunosorbent assay kit according to the
manufacturer’s instructions (Diaclone).16 The absorbance at 450
nm was measured, and concentrations were determined by means
of interpolation of a standard calibration curve. The lower limit of
detection of IL-6 was 0.78 pg/mL. Human recombinant IL-6 was
from Sigma (1-1395).
Measurement of Apoptosis
Apoptosis of variously treated cardiomyocytes was determined on
the basis of nuclear condensation with Hoechst staining.17 Cardi-
omyocytes were stained with 1 g/mL Hoescht 33342 trihydro-
chloride trihydrate (Molecular Probes) for detection of apoptotic
nuclei. Dishes were analyzed at 20 magnification by using a
Leica inverted deconvolution microscope with a coupled camera.
Apoptotic cells were identified by their increased fluorescence
caused by chromatin condensation and pyknotic morphology. A
minimum of 300 nuclei were counted per field, and each data point
consisted of 4 randomly selected fields. The measurement of
cardiomyocyte apoptosis with Hoechst staining was found to cor-
relate with, but was more sensitive than, that based on TdT-
mediated dUTP nick-end labeling labeling with the APO-BRDU
kit and enumeration by means of flow cytometry (FACScan/CELL
Quest system, BD Biosciences) and that based on Western mea-
surement of cleaved caspase-3 Asp175 antibody (Cell Signaling).
The percentage of apoptosis was determined as the ratio of apo-
ptotic nuclei/total Hoechst-positive nuclei, and statistical compar-
isons were made with Openlab 3.1.5 software. Statistical evalua-
tion of intervention and cell type effects relied on a paired t test or
1-way analysis of variance. Data are expressed as standard error
of the mean.
Synthesis and Transfection of ILK-Specific
Short-Interfering RNA Molecules
Single-stranded short-interfering RNA (siRNA) were transcribed
and annealed with a commercial kit, as outlined in the supplier’s
manual (Silencer Kit, Ambion). The following sequences were
used to construct ILK siRNA: ILK1, 50-AAGGGGACCACCCG-
CACTCGG-30; ILK2, 50-AAGGCACCAATTTCGTCGTGG-30;
and ILK3, 50-AAGCTCAACGAGAATCACTCT-30.
The specificity of ILK siRNA targeting vector has been
previously shown.18 GAPDH control siRNA was provided with
the Silencer siRNA construction kit. Transient transfections of
NRCMs were carried out using 6 L of Lipofectin reagent
(Invitrogen), according to the manufacturer’s instructions. To
quantitate the extent of knockdown of ILK protein, horseradish
peroxidase– conjugated immunoglobulin G was used as a sec-
ondary antibody, and ILK immunocomplexes were visualized
with an enhanced chemiluminescence detection reagent (Am-
ersham Pharmacia Biotech) and quantified by means of densi-
tometry.
Results
Gene Expression Analysis Reveals an Anti-
inflammatory Transcriptional Response in HFCMs
Gene-wise clustering, as shown in Figure 1, reveals 4 tem-
porally distinct expression strata: A, repression during I/R;
and Cardiovascular Surgery ● Volume 129, Number 5 1131
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DB, repression during ischemia; C, activation during isch-
emia, reperfusion, or both; and D, activation during isch-
emia and repression during reperfusion. The annotation of
significant genes and corresponding expression values are
indicated in Table 1. Noteworthy was the significant repres-
sion of IL-6 transcription during ischemia and especially
during reperfusion to 58% of preischemic levels by means
of microarray analysis and to 25%  11% by means of
qPCR measurement.
The Fetal Cardiomyocyte is Resistant to Apoptotic
Stimuli
The rate of apoptosis measured with Hoechst staining, as
shown in Figure 2, was significantly lower in the fetal
cardiomyocytes (relative to that observed in neonatal rat–
derived cardiomyocytes) in response to increasing duration
of ischemia with or without of reperfusion (P  .05 for rat
vs human cardiomyocytes, analysis of variance). Exogenous
IL-6 (250 ng/mL) caused a similar approximately 3- to
4-fold increase in apoptosis that was maximal at 3 hours of
exposure in both NRCMs (P  .012) and HFCMs (P 
.034) during normoxia and resulted in a significant increase
in the apoptotic rates in both cellular phenotypes after both
4 and 10 hours of ischemia (P  .05). IL-6–mediated fold
increases in apoptotic rates were greater in NRCMSs com-
Figure 2. Cardiomyocyte apoptotic rate during I/R. Primary cul-
tures of human fetal cardiomyocytes (HFCM) and 2- to 3-day
neonatal rat cardiomyocytes (NRCM) were exposed to simulated
ischemia with or without reperfusion for the indicated time
intervals. Cardiomyocytes were stained with 1 g/mL Hoescht
33342 for detection of apoptotic nuclei on the basis of typical
pyknotic nuclear morphology, and the results were expressed as
a fold change in the ratio of apoptotic to normal nuclei relative to
that of control levels. The rates of apoptosis increased signifi-
cantly with increasing duration of ischemia and reperfusion and
were higher in the neonatal rat cardiomyocytes compared with in
the human fetal cardiomyocytes (P < .05, analysis of variance). I,
Ischemia; R, reperfusion.pared with that in HFCMs (P  .035).
1132 The Journal of Thoracic and Cardiovascular Surgery ● MaIL-6 Signaling in HFCMs Is Uncoupled During I/R
IL-6R in HFCMs is expressed at low levels under control
conditions, increases during 4 hours of ischemia, and in-
creases to still higher levels after 4 hours of reperfusion
(Figure 3, A). STAT-3 is highly phosphorylated under con-
trol conditions, becomes almost completely dephosphory-
lated during ischemia, and is rephosphorylated to interme-
diate levels after reperfusion. Because STAT-3 is activated
by the signal transducer gp130 subunit, the conspicuous
decrease in gp130 levels during I/R is consistent with the
correspondent dephosphorylation of STAT-3. Unexpect-
edly, the addition of IL-6 resulted in a decrease in the levels
of IL-6R, gp130, and PY705-phosphorylated STAT-3 dur-
ing ischemia and after reperfusion. This finding might re-
flect counterregulatory degradation of IL-6R after ligation
by exogenously added soluble IL-6. There was a coincident
dephosphorylation of GSK-3 at Ser-9 during I/R, which
represents an inhibitory modification for this classically
antihypertrophic kinase.19 The addition of IL-6 increased
the extent of GSK-3 phosphorylation under control con-
ditions and after reperfusion in line with the prohypertro-
phic properties of this cytokine.5 Taken together, these data
indicate posttranslational inhibition of IL-6 signaling during
I/R and accords with the corresponding observed decrease
in IL-6 message levels (Table 1).
Deactivation of PKB/Akt and MAPK Signaling in
HFCMs During I/R
The relay system that transmits signals from gp130 to the
nucleus involves at least 3 distinct pathways of protein
phosphorylation: the JAK/STAT,20 PI3-K,21 and Raf-1/
MEK/MAPK20 pathways. Western analysis demonstrates
dephosphorylation of PKB/Akt at Ser-473 at 10 hours of
ischemia (Figure 3, B), although sequential measurements
indicated an easily detectable loss of phosphorylation within
30 minutes of ischemia (data not shown). A decrease of
similar magnitude in the phosphorylation of the p42/44
isoform of MAPK was evident during ischemia, with partial
reperfusion-mediated rephosphorylation (Figure 3, B). In
concert with the reduction in MAPK message levels by means
of microarray analysis (Table 1), this posttranslational modi-
fication would predict deactivation of MAPK-mediated signal-
ing during I/R. The finding that the stress-activated serine-
threonine kinase/c-jun N-terminal kinase (SAPK/JNK),
exhibited an increase in the (T183/Y185) phosphorylation
signal during ischemia (Figure 3, B) indicates that the ob-
served modifications in MAPK, PKB/Akt, and GSK-3 do
not simply reflect nonspecific global protein dephosphory-
lation events. Because activation of SAPK/JNK has been
linked to IL-6 gene expression on the basis of gene disrup-
tion in mouse embryonic fibroblasts,22 the lack of activation
of this kinase during reperfusion is consistent with the
generalized and concomitant repression of IL-6 signaling
demonstrated in the HFCMs.
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DILK Knockdown Protects Against Cardiomyocyte
Stress-induced Apoptosis
Data on the effects of ILK knockdown in protection against
cardiomyocyte stress-induced apoptosis are shown in Figure
4. ILK is a novel prohypertrophic kinase that causes phos-
phorylation of PKB/Akt and GSK-3.18 We asked whether
siRNA-mediated suppression of this proproliferative kinase,
which should mimic the signaling effects observed in the
fetal cardiomyocytes, could influence apoptotic threshold in
the NRCMs during I/R. As shown in the insert of Figure 4,
lipofectamine-mediated transfection of the ILK-specific
siRNAs, but not the GAPDH siRNA, resulted in substantial
(42%, P  .02) knockdown of ILK expression in NRCMs
as determined by means of Western blot analysis at 72 hours
after transduction. Exposure of ILK-silenced NRCMs to 4
hours of ischemia and 4 hours of reperfusion resulted in an
approximate 50% decrease in the apoptosis rate in compar-
ison with that seen in lipofectamine-only controls (P 
.031).
Discussion
A major finding in the present study is that the HFCM
Figure 3. A, Deactivation of IL-6 pathway during ischem
lysates from human fetal cardiomyocytes at control (C
hours of reperfusion (Isch/Rep) with and without additi
as indicated at the top of each lane. Immunoblots w
against components of the IL-6 signaling cascade as in
of IL-6 signaling during ischemia and reperfusion, as d
bands indicate equal protein loading in each lane, w
shown here represent 3 experiments exhibiting sim
ischemia-reperfusion. Western blot analysis was per
control (Ctrl), after 10 and 24 hours of simulated isch
Immunoblots were performed with both total and phosp
The results indicate that deactivating dephosphoryla
rephosphorylation evident after reperfusion, whereas t
results shown here represent 3 experiments exhibitinexhibits resilience against proapoptotic stimuli. This was
The Journal of Thoracicevident in the relative attenuation of cardiomyocyte apopto-
sis in comparison with that observed in a more mature
cellular phenotype in response to simulated I/R and exoge-
nous IL-6 exposure.
Genome expression profiling in the fetal cardiomyocyte
revealed a conspicuous repression, or lack of induction, of
IL-6 transcription during ischemia and especially during
reperfusion (58% of preischemic levels by means of mi-
croarray, 25% by means of qPCR). IL-6 is a multifunctional
cytokine with proproliferative and prohypertrophic proper-
ties in the heart.23 Upregulation of serum24 and myocardial
levels of pro-inflammatory cytokines (tumor necrosis factor
, IL-1, and IL-6) have been reported in infants with tetral-
ogy of Fallot,25 and increased IL-6 message is found in rat
hearts undergoing I/R.26 However, the specific alterations in
the IL-6 signaling pathway induced in the human cardio-
myocyte during I/R are unknown, and it is unresolved in the
literature as to whether a stress-induced increase in circu-
lating IL-6 levels represents a cardiomyocyte-protective or
cardiomyocyte-injurious response.
Our results indicate that the IL-6 pathway is inhibited at
multiple levels of regulation in HFCMs in response to I/R,
eperfusion. Western blot analysis was performed with
fter 4 hours of simulated ischemia (Isch), and after 4
recombinant IL-6 (250 ng/mL) at the onset of ischemia,
performed with total or phosphor-specific antibodies
ed, and taken together, the results reveal deactivation
ssed in the text. Total STAT-3 and GSK-3 expression
was also confirmed with actin controls. The results
effects. B, Kinase-specific dephosphorylation during
ed with lysates from human fetal cardiomyocytes at
(Isch), and after 10 hours of reperfusion (Isch/Rep).
pecific antibodies against PKB/Akt, MAPK, and SAPK.
of PKB/Akt and MAPK occurs during ischemia, with
pposite phosphorylation events occur with SAPK. The
ilar effects. Abbreviations are defined in the text.ia-r
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g simincluding gp130 receptor expression, dephosphorylation of
and Cardiovascular Surgery ● Volume 129, Number 5 1133
Surgery for Congenital Heart Disease Coles et al
CH
Dcytoplasmic, IL-6–dependent kinases (STAT-3, PKB/Akt,
and GSK-3), and IL-6 transcription. Reduced STAT-3
phosphorylation and IL-6 transcription could result from
downregulation of gp130 expression because this represents
the proximal signaling module of the IL-6 receptor com-
plex,8,9 despite the finding of a concomitant increase in the
IL-6R subunit during both the ischemic and reperfusion
phases. The reason for downregulation of gp130 expression
is unknown. Ischemia-induced disruption of membrane
lipid rafts plausibly accounts for this finding because IL-6
receptor complex localization and STAT-3 signal transduc-
tion are raft dependent.27
The finding that IL-6 potentiates stress-induced cardio-
myocyte apoptosis appears to conflict with previous reports
demonstrating cardioprotective properties of this cyto-
kine.5,28 It might be speculated, however, that the mitogenic
and prohypertrophic state associated with IL-6 stimulation
could be energetically unfavorable under conditions of se-
vere oxygen deprivation preceding reoxygenation, espe-
cially because IL-6 signaling has been linked to the gener-
ation of reactive oxygen species.29 The use of unbiased
genome profiling provides further support for the idea that
the HFCMs acquire a quiescent phenotype in response to
oxygen restriction, including the finding of a significant
reduction in the expression of MAPK 1 (Table 1). Activa-
tion of the MAPK cascade promotes an activating phos-
Figure 4. ILK suppression protects against I/R-induced apoptosis.
Neonatal rat cardiomyocytes were transduced with lipo-
fectamine only or lipofectamine containing ILK-targeted siRNA
and exposed to 4 hours of ischemia and 4 hours of reperfusion
(I/R), and the relative rates of apoptosis were quantitated with
Hoescht 33342 staining, as described in the text. Exposure of
ILK-silenced neonatal rat cardiomyocytes to 4 hours of ischemia
and 4 hours of reperfusion resulted in an approximate 50% de-
crease (P  .031) in the apoptosis rate in comparison with
lipofectamine-only controls (Ctrl). As shown in the insert, lipo-
fectamine-mediated transfection of the ILK-specific siRNAs re-
sulted in substantial (42%, P .02) knockdown of ILK expression,
as determined by means of Western blot analysis at 72 hours after
transfection. Abbreviations are defined in the text.phorylation of the nuclear factor for IL-6, also termed
1134 The Journal of Thoracic and Cardiovascular Surgery ● MaC/EBP, a member of the CCAAT/enhancer-binding pro-
tein (c/EBP) family of transcription factors. Nuclear factor
for IL-6 binds to a regulatory element in the IL-6 promoter
that is essential for induction of IL-6 transcription after
treatment with tumor necrosis factor  and IL-1.30 Dein-
duction of the MAPK signaling cascade, resulting from both
decreased transcript and protein phosphorylation levels ob-
served in the HFCM, might serve the energetically benefi-
cial purpose of dampening agonist-induced, proinflamma-
tory, and proproliferative signaling during I/R. IL-6
signaling might involve PI3-K–dependent, as well as
STAT-3 and MAPK, pathways.21 Our data also indicate that
deactivation of the PI3-K–dependent kinase PKB/Akt oc-
curs in the HFCMs during I/R, thereby nullifying potential
activation of IL-6 signaling through this collateral pathway.
ILK is a prohypertrophic kinase that is regulated in a
PI3-K–dependent manner after distinct signal inputs from
integrins and growth factor receptor tyrosine kinases.18 ILK
causes phosphorylation of PKB/Akt and GSK-3,18 post-
translational modifications that are diametrically opposite to
those that were observed in HFCMs exposed to ischemic
stress. Therefore we used siRNA-mediated silencing of ILK
to recapitulate the fetal response in the more apoptosis-
prone rat cardiomyocyte model. This manipulation revealed
an antiapoptotic effect of ILK knockdown and provides
additional indirect evidence that inhibition of prohypertro-
phic signaling might represent a cardioprotective strategy
under conditions of severe oxygen deprivation.
The induction of the antioxidant gene metallothionein I
observed in the fetal cardiomyocyte transcriptional profile
during I/R suggests an additional explanation for the apo-
ptosis resistance evident in this cellular phenotype because
this antioxidant has been shown to directly potentiate anti-
apoptotic signal transduction, as well as to mitigate redox-
mediated injury.31 The functional significance of other dif-
ferentially expressed genes identified in this study (Table 1),
either singly or in combinatorial permutations, will require
further experimentation conducted in both vulnerable and
apoptosis-resistant cardiomyocyte phenotypes involving
gene-specific gain- and loss-of-function strategies.
Taken together, our data support the general conclusion
that the HFCM represents a useful biosynthetic platform for
the identification of innate cardioprotective responses at the
molecular level. The adaptive stress response exemplified
by the fetal cardiomyocyte implicates the IL-6 pathway as
an important and therapeutically relevant arbiter of cellular
survival.
Limitations to the Study
Our data indicate that the isolated HFCM is more resistant
to apoptosis induction after exposure to simulated I/R than
that of the neonatal rat. The difference in stress-induced
apoptotic threshold is explainable on the basis of either
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Dspecies-related or development stage–related differences in-
herent in these distinct cellular phenotypes. The elucidation
of developmental stage-specific aspects of the human car-
diomyocyte stress response would require a comparative
analysis of human neonatal or adult cardiomyocytes with
that of the fetal phenotype. The fact that postnatal human
cardiomyocytes have an inherently greater susceptibility to
apoptosis during in vitro culture renders such studies diffi-
cult and implies that cardiomyocyte stress resistance de-
grades with increasing maturation. Nevertheless, our study
is directed to the investigation of IL-6 signaling during
redox-induced stress in the apoptosis-resistant HFCM phe-
notype and does not specifically address the developmental
aspects of this response.
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Discussion
Dr W. Randolph Chitwood, Jr (Greenville, NC). It is a fascinat-
ing study. Is there age dependency? If you let these cells go out
longer in time, is there a change?
Dr Coles. We have not successfully cultured them for more
than about 2 weeks.
Dr Chitwood. What would you think would happen at a
month?
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DDr Coles. Well, I think in culture you can have unanticipated
effects, and sometimes the cells will dedifferentiate.
Dr Chitwood. So they might differentiate from being a cardi-
omyocyte and become something else.
Dr Coles. Correct. However, longer-term studies would be
important and might reveal phenotypic differences unique to the
fetal cell.
Dr Frank A. Pigula (Boston, Mass). John, that was fasci-
nating. I think it would be particularly interesting to look at
postnatal myocardial expression to see whether there is any
difference between the two. And the only other question that
comes to my mind is that these hearts, by virtue of how you
obtain them, have been preconditioned to some degree, and I
wonder whether that has any influence on the ultimate genotype
and the expressions.
1136 The Journal of Thoracic and Cardiovascular Surgery ● MaDr Coles. Those are both fair points.
What we want to do is look at more apoptosis- vulnerable
phenotypes, including, for example, cardiomyocytes derived
from patients with congenital heart disease, such as tetralogy of
Fallot.
Those cells are difficult to grow, however, which, I think,
speaks to the fact that they are less resilient than the fetal
phenotype. But I agree that if we can look at gain- and loss-
of-function manipulations affecting the IL-6 pathway in cells
such as tetralogy cells, this will help reinforce our findings
regarding the importance of the IL-6 pathway. Preconditioning
effects, if any, inherent in the cell-isolation procedure, would be
difficult to measure but presumably would be factored out by
comparison with more mature cellular phenotypes using the
same protocol.
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